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Abstract.
Background: Publication of comprehensive clinical care guidelines for Duchenne muscular dystrophy (DMD) in 2010 was a
milestone for DMD patient management. Our CARE-NMD survey investigates the neuromuscular, medical, and psychosocial
care of DMD patients in Europe, and compares it to the guidelines.
Methods: A cross-sectional survey of 1677 patients contacted via the TREAT-NMD patient registries was conducted using
self-report questionnaires in seven European countries.
Results: Survey respondents were 861 children and 201 adults. Data describe a European DMD population with mean
age of 13.0 years (range 0.8–46.2) of whom 53% had lost ambulation (at 10.3 years of age, median). Corticosteroid med-
ication raised the median age for ambulatory loss from 10.1 years in patients never medicated to 11.4 years in patients
who received steroids (p < 0.0001). The majority of patients reported receiving care in line with guidelines, although
we identified significant differences between countries and important shortcomings in prevention and treatment. Sum-
marised, 35% of patients aged ≥ nine years received no corticosteroid medication, 24% of all patients received no regular
physiotherapy, echocardiograms were not performed regularly in 22% of patients, pulmonary function was not regularly
assessed in 71% of non-ambulatory patients. Patients with regular follow-up by neuromuscular specialists were more
likely to receive care according to guidelines, were better satisfied, and experienced shorter unplanned hospitalization
periods.
Keywords: Duchenne muscular dystrophy, standards of care, corticosteroid treatment, functional status
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe
form of muscular dystrophy, affecting one in
3,800–6,300 live male births [1]. The natural dis-
ease course is characterised by progressive muscle
weakness leading to ambulatory loss by 7–12 years
of age [2]. Respiratory insufficiency and cardiomy-
opathy develop in the second decade, and can cause
early death. Even though DMD remains incurable,
proactive symptomatic, multidisciplinary treatment
can raise life expectancy into the fourth decade.
Similar to other rare diseases, a treating physician
with disease-specific clinical knowledge and experi-
ence is imperative for best-practice treatment. The
publication of standardised care guidelines [3, 4]
in 2010 was an important step towards improving
DMD patient care. These guidelines were repro-
duced as “family guides”, that are now translated
into 37 languages, and distributed to patients and
health care providers via patient organisations, the
TREAT-NMD network, and patient registries. We set
out to survey the extent to which these guidelines have
been incorporated into clinical practice across Euro-
pean countries in both Eastern and Western regions.
Healthcare research in rare diseases is challenging,
with patient registries often the only resource iden-
tifying patients with a given disease. The objective
of the EU-financed CARE-NMD project (www.care-
nmd.eu) was to evaluate current care and quality
of life in DMD patients in Europe. Here we
present information describing current care of >1,000
children and adults with DMD in seven European
countries.
METHODS
Patients
We conducted a cross-sectional, international sur-
vey on care practices and quality of life in DMD
patients in Bulgaria, the Czech Republic, Denmark,
Germany, Hungary, Poland, and the United Kingdom.
Countries were selected because of well-established
DMD patient registries and to broadly represent dif-
ferent healthcare systems and public expenditure on
health. The health expenditure to gross domestic
product ratio is below the EU average in all Eastern
European and above the average in all Western Euro-
pean countries participating in this project. Therefore
we compared key outcome measures between the two
groups of countries. Children and adults with DMD
were recruited through direct contact from TREAT-
NMD national DMD patient registries. Patient
registration in these national registries is voluntary.
In Germany and the United Kingdom registration is
initiated by the patients/families themselves while
the other countries use a clinic-based approach for
registration. All registries store patient age with
clinical and genetic details [5]. Prior to our sur-
vey, each local CARE-NMD project team contacted
national patient organisations to encourage regis-
tration. Every patient registered as having DMD
was invited to participate in the survey. The data
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presented here is only based on self-report of patients
and their families. This study was approved by
the ethics committee in Freiburg, Germany, and
the TREAT-NMD Global Database Oversight Com-
mittee (http://www.treat-nmd.eu/about/governance/
tgdoc/).
Data collection and evaluation
Questionnaire development and methods of dis-
tribution are described in the supplemental material.
Data were collected between September 2011 and
April 2012, imported into a single SPSS (Version
22) database, then analysed using SPSS and Excel.
The Kolmogorov-Smirnov test was used to test for
a normal data distribution. Group parameters were
compared using the Wilcoxon test when data were
not normally distributed, and the Student’s t-test or
ANOVA when normally distributed. Cox regression
analysis was used to analyse factors influencing age
at loss of ambulation.
RESULTS
Surveyed patient cohort represents a European
cross-section
Of the 1180 returned questionnaires, 118 were
excluded from data analysis because the question-
naire was submitted empty, answered twice (online)
by the same patient, or the clinical data or reg-
istry categorised the patient as Becker muscular
dystrophy. Cleansing yielded 1062 datasets (final
response rate 63.3%) for analysis. Patient distribu-
tion was skewed towards Western European countries
with the exception of Poland. Patients ranged from
0.8 to 46.2 years of age in the surveyed cohort.
Mean patient age was considerably higher in Dan-
ish patients, reflecting more adult survey participants
(Table 1).
Current DMD Diagnosis in Europe
DMD can either be diagnosed by the absence of
dystrophin in a muscle biopsy or by genetic testing
for DMD mutations. Guidelines recommend genetic
testing for all patients, and 71.6% of DMD patients
reported additionally or exclusively receiving DMD
mutation screening (Table 1). Our survey identi-
fied 302 patients, including 91 (30.1%) adults, who
self-reported never having received a genetic diag-
nostic confirmation, and detected country-specific
differences, with more frequent genetic testing in
Eastern than Western European countries (Table 1).
Of the 107 patients diagnosed ≤24 months prior to
the survey, 93.5% reported genetic testing. Across
all countries, 80.5% of patients had been informed
about the possibility of genetic counselling, but
only 65% felt that information provided was suf-
ficient. Separating responders who reported their
age into three age groups revealed that younger
patient generations were diagnosed significantly
earlier (Table 2).
Neuromuscular centre care shortened unplanned
hospital stay and provided care according to
standards guidelines
Regular (at least 1-2 times yearly) check-ups at a
neuromuscular centre are recommended. We hypoth-
esised patients were more likely to receive care
according to consensus guidelines at neuromuscu-
lar centres, and formed two subgroups for process
indicator evaluation. Most respondents visited a neu-
romuscular centre at least once yearly for a check-up
(Table 3), which we defined as “regular visitors”.
“Irregular visitors” included patients visiting cen-
tres less frequently or never. Patients never seeking
centre care claimed [1] centres were too far away
(n = 49), [2] they were not aware centres existed
(n = 19), or [3] they did not need a neuromuscular
specialist (n = 8). Regular visitors were significantly
younger than irregular visitors, received more fre-
quent cardiac and pulmonary check-ups, were more
likely to receive corticosteroid treatment, were bet-
ter informed about all surveyed aspects of DMD
(Fig. 2), and were more satisfied with overall treat-
ment. The degree of satisfaction was similar across
all age groups, but differed largely between countries,
with the highest satisfaction reported for Denmark
(Fig. 3). We expected hospital admissions would be
fewer in patients attending neuromuscular centres,
and compared regular and irregular visitors. Surpris-
ingly, the proportion of unplanned admissions did
not differ between groups, but the mean duration
of stay was significantly longer in irregular visitors
(Table 5).
Corticosteroid treatment in Europe prolongs
ambulatory phase in DMD patients
The outcome indicator “walking ability” was anal-
ysed and the influence of corticosteroid treatment
assessed. Ambulation was lost in 53.4% of responders
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at similar ages across all countries (Table 3). Steroid
treatment should be initiated when the child reaches
the plateau-phase, occurring around four to eight
years of age [3], inferring that DMD patients with
typical disease course who have reached nine years
of age should be taking or have tried corticos-
teroids. However, 34.8% of these 704 patients had
never taken corticosteroids, 52.8% because doc-
tors had not suggested and 44.2% because parents
objected to the treatment (Table 3). Steroid use dif-
fered substantially across the surveyed countries,
while starting age was similar (Table 3). Most
frequent reasons for discontinuing corticosteroid
treatment were ambulatory loss (n = 98) or intolerable
side effects (n = 88). Notably, only 21% of non-
ambulatory patients reported current corticosteroid
medication. We compared age at ambulatory loss in
steroid naı¨ve patients and patients who received cor-
ticosteroid treatment, regardless of age of initiation,
duration of treatment, or dose. Ambulation was lost
significantly later in corticosteroid-treated patients
(Fig. 1). This effect was independent of country, care
at a neuromuscular centre, or receipt of physiother-
apy, none of which significantly influenced age at
ambulatory loss.
Rehabilitative, cardiac and pulmonary
management is frequently below recommended
standards in Europe
Care standards recommend preventive measures
to minimize contractures starting in the presymp-
tomatic stage. The majority of our cohort reported
receiving stretching or physical exercises from a
qualified professional (7.4% = never), but extraor-
dinary differences existed between countries with
the highest provision in Germany (>90%) and the
lowest in the UK (<50%) (Table 3). Adults were
generally less likely than children to receive physio-
therapy (Table 2). It is unlikely that the 242 patients
who reported not currently receiving physiotherapy
were performing stretching exercises at home, since
patient/parent information levels about exercise were
inadequate in approximately half these responders.
Echocardiogram frequency was chosen as a pro-
cess indicator for cardiac care. Annual echocardio-
graphy is recommended in patients ≥10 years of age
to detect left ventricular dysfunction for early cardio-
protective treatment. Our survey revealed that almost
one quarter of patients, especially adults, did not
receive regular echocardiograms (Tables 2 and 4).
Table 1
Age and diagnostic history of our European DMD patient cohort broken down by country
Characteristica Total cohort Eastern Europe Western Europe
(n = 1062) (n = 328) (n = 734)
BG CZ HU PL DK GE UK
Number of patient
questionnaires sent out
1677 73 191 70 246 131 545 421
Response rate (%) 63% 55% 47% 81% 58% 67% 77% 54%
Number of patient
questionnaires evaluated
1062 40 89 57 142 88 420 226
(% total evaluated) (100%) (3.8%) (8.4%) (5.4%) (13.4%) (8.3%) (39.5%) (21.3%)
Number of adult patientsb 201/1062 8/40 11/89 5/57 16/142 43/88 77/420 41 /226
(proportion) (18.9%) (20%) (12.4%) (8.8%) (11.3%) (48.9%) (18.3%) (18.1%)
Mean patient age in
years ± SD at questionnaire
completion (n = 1062)
13.0 ± 7.2 13.7 ± 6.6 11.1 ± 5.3 10.5 ± 5.5 12.1 ± 6.1 20.3 ± 10.5 12.3 ± 6.9 12.9 ± 6.7
Mean patient age at diagnosis
in years ± SD
(n = 971/1062)
4.3 ± 2.5 6.4 ± 4.0 3.7 ± 0.8 4.6 ± 2.7 5.3 ± 1.4 4.6 ± 1.3 3.8 ± 2.4 4.1 ± 2.0
Mean time from report of first
symptoms to diagnosis in
years ± SD (n = 833/1062)
1.3 ± 1.8 2.0 ± 3.5 0.8 ± 1.2 1.9 ± 2.3 1.4 ± 2.0 1.3 ± 1.5 1.4 ± 1.8 1.1 ± 1.3
Patients reporting having
genetic testing for DMD
mutations (n = 1062)
71.6% 90.0% 87.6% 96.5% 79.6% 53.4% 79.8% 42.5%
Patients reporting diagnosis
by muscle biopsy
(n = 1062)
49.3% 20.0% 53.9% 42.1% 57.0% 58.0% 48.3% 48.2%
SD = standard deviation, BG = Bulgaria, CZ = Czech Republic, GE = Germany, DK = Denmark, HU = Hungary, PL = Poland, UK = United
Kingdom. aNumbers in row titles indicate the total number of evaluable responses in our cohort of 1062 patients. bDefined as ≥18 years of
age.
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Fig. 1. The Kaplan-Meier estimates and their confidence intervals (shaded areas) show a clear distinction that patients with current steroid
use show significantly loss of ambulation. The Kaplan-Meier estimate of the median time of loss of ambulation (x-axis) is 10.08 (9.58–10.50
95% Confidence Interval) years versus 11.42 (10.45–11.50 95% CI) years in the “never” versus “past or current steroid use” groups. The
tick marks indicate right-censored data, i.e. patients who were still ambulatory at the time of recording. The ‘numbers at risk’ are shown
below the plot and correspond to the x-axis, indicating how many patients were available for estimation. Cox regression analysis, p < 0.0001
in the corticosteroid-user group, with 1.34 years difference between group medians.
Table 2
Results of selected outcome and care indicators of DMD patient care for the whole cohort and different age groups in the cohort
Characteristic Whole cohort Children adultsc
Younga Intermediateb
Mean patient age in years ± SD at diagnosisd 4.3 ± 2.5 2.3 ± 1.3 4.4 ± 2.3 5.2 ± 2.9
(n = 971/1062)e (n = 122/137) (n = 665/724) (n = 184/201)
Mean time from report of first symptoms
to diagnosis in yearsf
1.3 ± 1.8 0.7 ± 0.8 1.4 ± 1.7 1.6 ± 2.3
(n = 833/1062) (n = 95/137) (n = 573/724) (n = 165/201)
Patients receiving physiotherapy 72.8% 78.1% 67.9%
(n = 1015/1062) (n = 819/861) (n = 196/201)
Patients (≥10 years of age) receiving
echocardiography according to guidelinesg
77.9% 82.2% 67.4%
(n = 635/660) (n = 439/459) (n = 196/201)
Patients who reported unplanned hospital
admissions within past 2 years
13.6% 8.9% 25.4%
(n = 1062) (n = 861) (n = 201)
a<6 years of age at questionnaire response (n = 137/1062). b6–17 years of age at questionnaire response (n = 724/1062). c ≥18 years of age
at questionnaire response (n = 201/1062). dAnova between all age groups = p < 0.0001. eNumbers in parenthesis indicate the total number of
evaluable responses per the total number of patients in our cohort who correspond to the descriptor. f Anova between all age groups = p < 0.01.
Both muscle biopsy and genetic testing diagnoses were considered. gRecommended once yearly.
Echocardiogram frequency differed markedly
between countries, with lower frequencies in some
Eastern European countries and Denmark (Table 3).
A small proportion (n = 174) could report their left
ventricular ejection fraction (LVEF) of whom 72
patients reported an LVEF <55%, signifying car-
diomyopathy [7]. Of these, only 69.4% received treat-
ment for cardiomyopathy with either beta-blockers
or angiotensin-converting enzyme inhibitors. Of the
102 patients reporting an LVEF ≥55%, 27.5% were
receiving prophylactic medication.
Care guidelines recommend pulmonary function
assessment yearly in ambulatory and twice yearly
in non-ambulatory patients (≥6 years). Adherence
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Table 3
Selected outcome and process indicators for patient care in our European DMD patient cohort broken down by country
Characteristica Total cohort Eastern Europe Western Europe
(n = 328/1062) (n = 734/1062)
BG CZ HU PL DK GE UK
Patients reporting loss of ambulation
(n = 567/1049)
53.4% 62.5% 49.4% 50.0% 50.7% 75.0% 52.4% 50.5%
Mean patient age at loss of
ambulation in years ± SD
(n = 549/567)
10.4b ± 2.4 10.2 ± 2.0 9.9 ± 1.8 9.8 ± 3.1 9.9 ± 1.8 9.9 ± 2.4 10.9 ± 2.7 10.3 ± 2.1
Non-ambulatory patients reporting
being able to sit unsupported
(n = 548/567)
51.8% 66.7% 75.0% 85.2% 49.2% 11.1% 51.6% 56.5%
Non-ambulatory patients requiring
a spinal brace to sitc (n = 548/567) 44.0% 29.2% 22.7% 14.8% 46.0% 79.4% 46.6% 36.1%
Non-ambulatory patients incapable
of sitting (n = 548/567)
4.2% 0% 2.3% 0% 4.8% 9.5% 1.8% 7.4%
Non-ambulatory patients reporting
current steroid use (552/567)
21.0% 8.0% 7.5% 18.5% 22.2% 6.2% 21.6% 35.7%
Mean age in years ± SD of steroid
treatment start (n = 478/637)
6.1 ± 2.4 6.4 ± 1.9 6.9 ± 2.3 6.5 ± 2.2 5.9 ± 2.6 5.8 ± 2.0 5.8 ± 2.5 6.4 ± 2.4
Patients ≥9 years of age
(n = 704/730) reporting current
or past steroid use 65.2% 29.0% 32.0% 53.1% 71.4% 34.2% 72.8% 83.6%
Mean age in years ± SD of steroid
treatment start in patients aged
≥9 years (n = 335/730) 6.6 ± 2.6 7.2 ± 1.9 7.4 ± 2.6 7.8 ± 1.1 6.5 ± 2.9 6.1 ± 2.0 6.1 ± 2.7 6.9 ± 2.5
Patients regularlyd visiting
a neuromuscular centre
(n = 1027/1062)
81.9% 43.6% 82.1% 82.5% 56.9% 81.6% 88.5% 92.1%
Patients receiving physiotherapy
(n = 1015/1062)
76.2% 53.8% 51.9% 76.8% 84.1% 90.7% 92.0% 48.4%
Sufficient instructions to perform
exercises in patients without
current physiotherapy
(n = 238/240)
53.3% 16.7% 56.4% 25.0% 50.0% 62.5% 21.9% 70.6%
Patients (≥ 10 years of age) receiving
echocardiography ≥ once yearly
(n = 633/660)
77.9% 64.0% 65.9% 85.2% 54.2% 63.0% 90.7% 81.0%
Ambulatory patients (≥6 years
of age), receiving lung function
testinge according to international
care recommendationsf
(n = 336/348)
62.8% 76.9% 44.8% 71.4% 32.0% 61.1% 74.2% 66.3%
Non-ambulatory patients (≥6 years
of age), receiving lung function
testing according to international
care recommendationse
(n = 547/567)
30.5% 4.3% 5.0% 14.8% 5.8% 18.5% 44.1% 45.5%
Non-ambulatory patients reporting
spinal inspection (n = 540/567)g
20.2% 4.3% 7.3% 11.1% 2.8% 7.9% 32.2% 26.0%
SD = standard deviation, BG = Bulgaria, CZ = Czech Republic, GE = Germany, DK = Denmark, HU = Hungary, PL = Poland, UK = United
Kingdom. an number in row and column titles indicate the total number of evaluable responses per the total number of patients in our cohort
who correspond to the descriptor. bRange of age at loss of ambulation was 1.33–20.58 years and median 10.3 years. cMean age = 22.0 ± 8.3
years. dRegularly defined as at least 1-2 times per year. eLung function measured by forced vital capacity (FVC). f International care
recommendation recommends measuring FVC annually in ambulatory patients and bi-annually in non-ambulatory patients. gMinimal
recommendations are visual inspection every 6 months.
to guidelines was low in ambulatory and strikingly
bad in non-ambulatory patients (Table 4), and pro-
nounced differences between Eastern and Western
European countries were revealed (Table 3). Many
patients reported being insufficiently informed about
DMD-related breathing problems (Fig. 2). Our sur-
vey identified lung function awareness as a problem
area in DMD care, with only 31.3% of ambulatory
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and 39.9% of non-ambulatory patients knowing their
current (<12 months) FVC. We surveyed need or
use of breathing assistance in all 1062 patients, and
154 patients (mean age 26.6 ± 6.5 years) reported
using mechanical ventilation. Of patients not using
mechanical ventilation, 20.6% (7/34) reported an
FVC <20%. This subgroup is very likely to benefit
from ventilatory support [7].
DISCUSSION
Here we present results from the largest cross-
sectional survey conducted on DMD patients in
Europe. Results comprehensively describe patient
health status and current care practice in East-
ern and Western European countries. Our analyses
identify areas where care does not reach internation-
ally defined recommendations and highlights trends
in patient care. Our patient-centred approach goes
beyond registry information and provides an insight
into real-world experiences of DMD care. Patient
registries represent a unique source for obtaining
data from large cohorts of patients with a confirmed
diagnosis of DMD, since hospital coding uses a
single ICD code for all muscular dystrophy types.
Since registry participants are likely to be more
actively engaged in their medical care and receive bet-
ter care than unregistered patients, we attempted to
increase registered patient numbers in collaboration
with patient advocacy groups prior to survey to reduce
this possible bias. The exact prevalence of DMD is
not known for the different European countries and
probably varies significantly according to differences
in mortality. For most countries studied in this project
it can be estimated that less than half of the total DMD
population are captured in patient registries. There-
fore non-registered patients and non-responders add
additional bias to our results. Due to the anonymity of
the survey it was not possible to further analyse this
bias by comparing characteristics of responders and
non-responders. In addition, it might be possible that
some respondents were familiar with the care recom-
mendations and answered questions accordingly even
if examinations did not really happen (desirability
bias). In addition, self-reporting may introduce error
from incorrect comprehension of questions or inac-
curate memory of treatment/care. This may explain
the extremely low number of UK patients reporting
genetic testing, while the national registry reports
all registered patients had genetic confirmation
of DMD.
Fig. 2. Percentage of patients that felt sufficiently informed by
their physician about various aspects of Duchenne muscular dys-
trophy. The group of patients reporting insufficient information
about breathing problems was composed of 47.1% ambulatory and
61.0% non-ambulatory patients.
Fig. 3. shows the percentages of patients with Duchenne mus-
cular dystrophy of each country reporting the degree of overall
satisfaction with the medical treatment on a four-point scale
(very satisfied, rather satisfied, rather dissatisfied, not satis-
fied). The absolute number of evaluated questionnaires (n)
is indicated for the whole cohort and for each country at
the x-axis. BG = Bulgaria, CZ = Czech Republic, GE = Germany,
DK = Denmark, HU = Hungary, PL = Poland, UK = United King-
dom.
Our data reflect patient and family perspectives on
DMD care, and indicate a large proportion of patients
(i) feel insufficiently informed about all care aspects
in the survey and (ii) are unaware of critical aspects
of their individual health, namely pulmonary or car-
diac function. Whether the information deficit reflects
insufficient provision or poor retention of information
is unclear. Regardless, our data identify an education
deficit that if rectified, could improve patient empow-
erment for appropriate monitoring and care. We did
not request names of care-giving centres/hospitals
to preserve patient anonymity, and thus quality of
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care in specific facilities cannot be determined from
our data. Our patient-centred survey approach put
restrictions on detail, since time required to complete
the survey was limited to achieve maximal evalu-
able responses. We balanced covering a wide range
of disease aspects with enough detail to sufficiently
analyse data. Therefore, this survey did not cover all
aspects of DMD care addressed in care standards. The
high response rate (63%) exceeded our expectations
compared to other surveys, and reflects the strong
interest of patients/families in assisting to improve
DMD care.
Early DMD diagnosis is necessary for early initi-
ation of preventive measures. Moreover, new gene-
specific approaches are more likely to be successful
if applied at an early stage of the condition. Patients
were ∼4 years old at diagnosis in most European
countries. This is younger than previously reported
in the UK and United States [8, 9]. Our analy-
sis reveals that DMD patients are being diagnosed
younger, likely reflecting improved access to diag-
nostics and increased primary physician awareness.
Affected families benefit from reduced time to diag-
nosis, since they spend less time with uncertainty
and have more time to consider family planning. Our
survey confirms genetic testing in nearly all newly
diagnosed patients, but reveals genetic testing still
does not reach all older European DMD patients.
Sufficient information about typical disease course
is crucial for care-providers, patients, and families,
since this influences medical care and personal plan-
ning for future education and living. We gathered
broad information describing patients’ current neu-
romuscular situations and disease course as well
as treatment and informedness level. Patients who
receive(d) corticosteroids lost ambulation later than
untreated patients, albeit the ambulatory time gained
was less than in other studies with probably more
uniform patient cohorts [10]. Overall mean ambula-
tory loss, regardless of corticosteroid use, was also
earlier (10.4y) than expected [11, 12]. Although our
study was not designed to analyse corticosteroid
influence on ambulation, it portrays real-life corticos-
teroid use in European patients, and despite patient
heterogeneity, supports the well-known beneficial
effect of corticosteroids on ambulation. Our results
concur with a another large observational study of
steroid-use in real-life practice in Japan [13]. Our data
reveal marked differences between countries, with
the lowest corticosteroid use in Bulgaria, the Czech
Republic, and Denmark. Economic reasons, insuf-
ficient information, or as yet unidentified cultural
or country-specific issues may discourage corticos-
teroid use. We recommend efforts be increased to
educate patients/parents in detail about corticosteroid
benefits and side-effect management to minimize
fear. The large majority of our cohort who were
regularly treated in centres had at least tried corti-
costeroids, in contrast to those treated elsewhere.
Care standards recommend physiotherapeutic pre-
ventive measures begin in the presymptomatic stage
and continue throughout life to minimize contractures
in upper and lower extremities, preserve function
and reduce pain. Our data show that just under a
quarter of children and one third of adults did not
receive any physiotherapy. Lack of professional phys-
iotherapy may partially be compensated by sufficient
instruction for in-home exercises. Our results con-
vey an urgent need to improve information transfer
to patients/families about the importance of regu-
lar stretching to improve success of professional
physiotherapy and training programmes for in-home
stretching exercises. Almost half of respondents were
non-ambulatory, emphasising the need for compre-
hensive optimised care focussing on maintaining
upper extremity motor function and managing scolio-
sis. Preserving hand function is essential for patients
to independently use a wheelchair, other assistive
devices, or computers, and to eat or take part in edu-
cation or a profession [14]. The mean age at which
hand function was lost was 26 years, but our oldest
patient still capable of using hands to move an elec-
tric wheelchair was 41.9 years old. Our survey and
other reports [15] suggest upper limb function varies
greatly and give proof-of-principle for maintaining
meaningful hand function into the fourth decade. The
current life expectancy of ≥30 years [16, 17] and a
mean “late-ambulatory II” age of 19 years from our
data indicate patients spend >10 years with impaired
hand function, emphasising the importance of pre-
ventive and therapeutic measures to maintain hand
function [14, 18]. Sitting ability facilitates mobility,
social participation, eating, and eye-level communi-
cation, but becomes impaired by scoliosis, a frequent
complication in non-ambulatory DMD patients [19,
20]. Standards recommend regular monitoring and
surgical correction for scoliosis in non-ambulatory
patients [4]. Efforts should be made to more consis-
tently realise this recommendation, since nearly 30%
of our surveyed non-ambulatory participants reported
never receiving spinal radiography or inspection.
Regular care from neuromuscular specialists is
recommended [4], and our survey supports that spe-
cialised neuromuscular centres provide best-practice
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Table 4
Results of process indicators for cardiac and pulmonary care in DMD patient subgroups
Characteristica Check-ups according to Less frequent check-ups No check-ups
recommendationb
Lung function testing in ambulatory
patients ≥6 years (n = 331/348)
63.7% 12.9% 23.3%
Lung function testing in non-ambulatory
patients ≥6 years (n = 546/567)
30.6% 59.3% 10.1%
Echocardiography in patients ≥10 years
(n = 635/660)
77.9% 17.7% 4.4%
an number in row titles indicate the total number of evaluable responses per the total number of patients in
our cohort who correspond to the descriptor. bInternational care recommendation recommends measuring forced
vital capacity annually in ambulatory patients and bi-annually in non-ambulatory patients ≥ six years of age and
echocardiography ≥ once yearly in patients aged ≥10 years.
Table 5
Results of selected outcome and care indicators for DMD patients regularly and irregularly seeking care
at a neuromuscular centre
Characteristic Regular visitorsa Irregular visitorsb Difference
(n = 841) (n = 186)
Mean patient age in years ± SD 12.1 ± 6.3 17.3 ± 9.3 p < 0.0001c
No regulard cardiac check ups 21.0% 52.3% p < 0.001e
No regulard pulmonary check-ups 30.9% 71.1% p < 0.001e
Satisfaction with treatment 83% 50% p < 0.001e
Patients ≥9 years of age reporting current
or past corticosteroid use 73.0% 37.2% p < 0.001e
Patients who reported unplanned
admissions to hospital 13.8% 15% n.s.
Mean duration of hospital stay
for the unplanned admissions 9.3 ± 3.7 23.0 ± 11.8 p < 0.05e
SD = standard deviation. aDefined as visiting a neuromuscular centre at least once yearly. bIncluding patients who
sought care less than once yearly (n = 78) or never (n = 109). cStudent’s t-test. dDefined as at least yearly. eWilcoxon
test.
care for DMD patients. Process indicators, including
sufficient information about disease aspects, regu-
lar assessments, and corticosteroid treatment, as well
as outcome indicators, including overall satisfac-
tion with medical care and unplanned hospital stay
duration, indicated patients regularly visiting neu-
romuscular centres were better situated. This is in
line with findings in patients with cystic fibrosis or
other life-limiting chronic conditions [21, 22]. Our
survey shows that 10% of patients (25% of adults)
never received care from a neuromuscular specialist.
Therefore, DMD care may be improved by bet-
ter information and better access to neuromuscular
centres. We confirmed that care from a neuromus-
cular specialist could reduce duration of stay during
unplanned hospital admissions.
Cardiomyopathy is a major source of morbid-
ity and mortality in DMD patients, especially in
the second decade [23]. Observational studies have
shown that -blockers [24] can delay progression of
left ventricular dysfunction. Our survey reveals that
nearly one third of patients meeting the criteria for
cardiomyopathy reported not receiving medical treat-
ment. An important first step to improve cardiac care
would be improving patient education, with the goal
of making the DMD patient an expert to increase
patient investment, especially at the transition from
paediatric to adult cardiac care [25].
Appropriate pulmonary care, including secretion
management and non-invasive ventilation, has prob-
ably the largest impact on quality of life and survival
in adolescent and adult DMD patients [16]. One quar-
ter of patients reporting a FVC <20% were without
mechanical ventilation, and the percentage is likely to
be even higher in patients who were not tested or did
not know their pulmonary function values. Although
many unplanned hospital admissions were attributed
to acute respiratory problems, we detected no correla-
tion between regular pulmonary function assessment
and unplanned hospitalisation.
Once considered a childhood disease, DMD must
now be redefined as a disease beginning in childhood
but continuing into adult life, making the transi-
tion from paediatric to adult-oriented healthcare ever
more important [26]. The lack of nearby neuromus-
cular centres for adult patients and reduced mobility
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in advanced disease stages contributed to the large
number of adults not receiving care from neuromus-
cular specialists. Our results emphasise the need for
a coordinated transition from child- to adult-centred
care and comprehensive, multidisciplinary care and
social support for the growing number of adults living
with DMD [27].
Our cross sectional survey of >1,000 European
DMD patients shows that despite development and
broad dissemination of multidisciplinary care guide-
lines many patients still do not receive recommended
interventions and treatments likely to improve qual-
ity of life. The neglected population is probably
underestimated by our survey, due to the unavoidable
bias associated with recruiting patients via patient
registries. Assuring the implementation of recom-
mended care standards remains the best way to ensure
the highest quality of life for DMD patients, and still
has room for improvement in Europe.
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